Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Chief Medical Officer | August 21, 2023 | August 23, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date August 21, 2023 · Filed August 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 11,010 |
Reported balance
After 2023-08-21 transaction · row 1
1 source rowRow 1 · 2023-08-21 · Sale · Disposed 1,490 · Balance 11,010 F1: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on September 9, 2022. F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.83, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on September 9, 2022.
F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.83, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2023 Filed Aug 23, 2023 21:59 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,490 | $16.65 | $24,815.50 |
DisclosureSEC source: 0001209191-23-047105 · doc4.xml · nonDerivative · entry 1 Lin Celia · CIK 0001859386 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,010 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on September 9, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.83, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0001209191-23-010510 · doc4.xml · derivative · entry 1 Lin Celia · CIK 0001859386 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: 1/48 of the total stock option will vest and become exercisable monthly on the same day of each month following February 15, 2023, subject to continuous service of the Reporting Person on each vesting date. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:11 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047170 · doc4.xml · nonDerivative · entry 1 Lin Celia · CIK 0001859386 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under Issuer's 2021 Equity Incentive Plan. One-third of the RSUs vest on August 20, 2023, rounded to the nearest whole share, and the remaining RSUs vest on August 20, 2024, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:11 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 52,412 | $0.00 Strike: $20.94 | $0.00 |
DisclosureSEC source: 0001209191-22-011222 · doc4.xml · derivative · entry 1 Lin Celia · CIK 0001859386 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,412 Underlying: Class A Common Stock · 52,412 shares Expires 2032-02-15 F1 · derivative.exercise_date: 1/48 of the total stock option will vest and become exercisable monthly on the same day of each month following February 16, 2022, subject to continuous service of the Reporting Person on each vesting date. Read SEC document |
| May 13, 2021 Filed May 18, 2021 00:33 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 16,916 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033334 · doc4.xml · derivative · entry 1 Lin Celia · CIK 0001859386 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,916 Underlying: Class A Common Stock · 16,916 shares Expires 2031-05-12 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 13, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.